Fact Checked

SurvivorNet Fact Checking and Medical Review Standards:  

The SurvivorNet News Team creates high quality medical information that complies with our industry leading standards for factual accuracy and sourcing from leading experts at academic medical institutions. Every news article is thoroughly fact-checked by our physician collaborators. We vet each piece of work for factual integrity, impartiality, and clearly label any professional conflicts.

All SurvivorNet articles adhere to the following standards:

  1. All studies and research papers cited are from reputable academic medical institutions or peer-reviewed journals.
  2. When we use data, statistics, or quotes these references link to the original source.
  3. All content related to new treatments, drugs, procedures, and so on must clearly describe availability, side effects, treatment target (such as triple negative breast cancer)
  4. All medical information on SurvivorNet is sourced from respected medical professionals with verified medical credentials and links are provided to these sources.
  5. We strive to give the reader relevant background information and include, clearly-sourced contextual health information in all articles. Readers are clearly alerted to any conflicts of interest from a medical source or the authors of a cited study.
/ Updated January 3rd, 2022

Are the Side Effects of Androgen Deprivation Therapy Worth the Risk?

NOW
PLAYING
Do You Know The Signs Of Testicular Cancer?
NOW
PLAYING
Announcement By Childless Soap Star That She Has Breast Cancer Raises Question Again: Are Women With No Kids More Likely To Get The Disease?
NOW
PLAYING
How Does a Patient Best Reduce the Risk of Breast Cancer Recurring?
NOW
PLAYING
April Is Testicular Cancer Awareness Month – Here's What You Should Know
NOW
PLAYING
How the Approval of Atezolizumab as Combination Therapy Changes the Scope of Melanoma Treatment
NOW
PLAYING
A SurvivorNet Guide to Early-Stage Cancer Detecting Blood Tests

Later Stage Treatment: New Treatment Developments

SEE MORE   

  • There are several new drugs and treatment options available for those facing advanced stage prostate cancer.
  • Two PARP inhibitors are currently FDA-approved: Lynparza (olaparib) and Rubraca (rucaparib).
  • Two newer androgen deprivation therapies include: Xtandi (enzalutamide) Erleada (apalutamide).

Later Stage Treatment: New Treatment Developments

  • There are several new drugs and treatment options available for those facing advanced stage prostate cancer.
  • Two PARP inhibitors are currently FDA-approved: Lynparza (olaparib) and Rubraca (rucaparib).
  • Two newer androgen deprivation therapies include: Xtandi (enzalutamide) Erleada (apalutamide).
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.